The invention relates to a carrier for administering biologically active compounds comprising one or more C1-C4 alcohols, polyols and polymers thereof, water and one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof. The carrier may be used in administering
The invention relates to a carrier for administering biologically active compounds comprising one or more C1-C4 alcohols, polyols and polymers thereof, water and one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof. The carrier may be used in administering biologically active compounds, in particular pharmaceuticals including cosmetic agents.
대표청구항▼
1. A carrier for administering biologically active compounds comprising one or more C1-C4 alcohols in an amount of 5 to 40%, water in an amount of 50 to 99%, and a combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate com
1. A carrier for administering biologically active compounds comprising one or more C1-C4 alcohols in an amount of 5 to 40%, water in an amount of 50 to 99%, and a combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate compounds in an amount of up to 11%, wherein the di-(electron transfer agent) phosphate compounds and the mono-(electron transfer agent) phosphate compounds are in the acid forms, and wherein the carrier is in the form of vesicles. 2. A carrier according to claim 1 in which the C1-C4 alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, and combinations thereof. 3. A carrier according to claim 2 in which the C1-C4 alcohol is ethanol. 4. A carrier according to claim 1 in which the C1-C4 alcohol is present in an amount of 10 to 30w/w %. 5. A carrier according to claim 1 in which the di- and/or mono-(electron transfer agent) phosphate compound is selected from the group consisting of hydroxy chroman phosphate compounds, phosphate compounds of quinols being the reduced forms of vitamin K1 and ubiquinone, hydroxy carotenoid phosphate compounds, calciferol phosphate compounds, and ascorbic acid phosphate compounds. 6. A carrier according to claim 5 in which the hydroxy chroman phosphate compounds are selected from the group consisting of alpha, beta, gamma and delta tocol phosphate compounds in enantiomeric and racemic forms. 7. A carrier according to claim 6 in which the tocol phosphate compound is a tocopheryl phosphate compound or a tocotrienol phosphate compound. 8. A carrier according to claim 7 in which the tocol phosphate compound is selected from the group consisting of di-tocopheryl phosphate compounds, di-tocopheryl di-phosphate compounds, di-tocotrienol phosphate compounds, mono-tocopheryl phosphate compounds, mono-tocopheryl di-phosphate compounds, and mono-tocotrienyl phosphate compounds. 9. A carrier according to claim 8 in which the tocol phosphate compound is a di-tocopheryl phosphate compound. 10. A carrier according to claim 1 in which the combination is a combination of a di-tocopheryl phosphate compound and a mono-tocopheryl phosphate compound. 11. A carrier according to claim 10 in which the w:w % ratio of mono-tocopheryl phosphate compound to di-tocopheryl phosphate compound is from 4:1 to 1:4. 12. A carrier according to claim 1 in which the combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate compounds is present in an amount of 1 to 11w/w %. 13. A carrier according to claim 1 in which water is in an amount of 60 to 95w/w %. 14. A carrier according to claim 1 in which the vesicles have a diameter of 50 to 10,000 nm. 15. A carrier according to claim 1 in which the vesicles partially or fully encapsulate the biologically active compound. 16. A process for the preparation of the carrier as defined in claim 1 which comprises the steps of: (a) combining the combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate compounds with the one or more C1-4 alcohols; and(b) adding water to the combination of step (a). 17. A formulation comprising a biologically active compound and a carrier, wherein the carrier comprises one or more C1-C4 alcohols in an amount of 5 to 40%, water in an amount of 50 to 99%, and a combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate compounds in an amount of up to 11%, wherein the di-(electron transfer agent) phosphate compounds and the mono-(electron transfer agent) phosphate compounds are in the acid forms. 18. A formulation according to claim 17 in which the biologically active compound is a pharmaceutical or a phosphorylated pharmaceutical. 19. A formulation according to claim 18 in which the pharmaceutical is selected from the group consisting of vitamins, phytochemicals, cosmetic agents, nutraceuticals, nutritional health or other supplements, hormones, peptides, polypeptides, proteins, amino acids, enzymes, nucleic acids, oligonucleotides, immunoglobulins, antibodies, vaccines, gene therapies, antioxidants, antimicrobial agents, antifungal agents, antiviral agents, anti herpes agents, and antibiotics. 20. A formulation according to claim 19 in which the pharmaceutical is selected from the group consisting of neuroleptic agents, narcotic analgesic agents, anti-inflammatory agents, non-steroidal anti-inflammatory agents, anti-arthritis agents, anti-obesity agents, anti-obesity peptides, lipoproteins, lipase inhibitors, vasodilators, corticosteroids, progestins, androgens, antiandrogens, anti-cancer agents, antihistamines, anti-angina agents, agents affecting the respiratory system, an allergic rhinitis pharmaceuticals, treatments for bleeding, antidyslipidaemic agents, anti-diabetic agents, insulin, hypoglycaemic agents, glucagon-like peptides, steroid hormones, growth hormones, growth hormone agonists, steroid hormone antagonists, growth hormone antagonists, octreotide, gonadotropin releasing hormones, leuprolide, human parathyroid hormone (PTH), human apolipoprotein, β-blockers, calcium channel blockers, anti-anxiety and hypnotic agents, non-barbituate sedatives, psychomotor stimulants, antidepressants, antiepileptics, cyclooxygenase 2 (COX2) inhibitors, opioid agonists, opioid antagonists, non-opioid analgesics, corticosteroids, anaesthetics, benzodiazepines, opioids, and anti-aging, anti-acne or anti-wrinkle agents. 21. A formulation according to claim 19 in which the pharmaceutical is selected from the group consisting of co-enzyme Q, human parathyroid hormone, insulin, glucagon-like peptide, morphine, oxycodone, diclofenac, lidocaine, propofol, timolol, acyclovir, clindamycin, tranexamic acid, vitamin K, folic acid, erythropoietin, iron, elastin, niacin, prostaglandins, nicotine, collagen, omega-3-fatty acids, glucosamine, grape seed extract, isoflavones and phytosterols, hydroquinone derivatives, retinol, and retinoic acid. 22. A formulation according to claim 20 in which the biologically active compound is present in an amount of up to 5w/w %. 23. A formulation according to claim 17 which further comprises one or more excipients. 24. A formulation according to claim 23 in which the excipients are selected from the group consisting of solvents, thickeners or gelling agents, surfactants, buffers, emollients, sweeteners, disintegrators, flavours, colours, preservatives, fragrances, electrolytes, and film foaming polymers. 25. A formulation according to claim 23 in which the excipients are present in an amount of up to 5w/w %. 26. A method for preparing the formulation as defined in claim 17 comprising the step of combining a biologically active compound with the carrier comprising one or more C1-C4 alcohols, water, and the combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate compounds. 27. A carrier according to claim 1 in which the C1-C4 alcohol is a polyol of a C1-C4 alcohol or a polymer of a C1-C4 alcohol. 28. A carrier according to claim 27 in which the polyol of a C1-C4 alcohol is a glycol, propylene glycol, polyethylene glycol or combinations thereof. 29. A formulation according to claim 17 in which the biologically active compound and carrier are formulated for parenteral, enteral, oral, topical, transdermal, ophthalmological, rectal, vaginal, intranasal, or intrapulmonary administration. 30. A formulation according to claim 17 in which the C1-C4 alcohol is selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, and combinations thereof. 31. A formulation according to claim 30 in which the C1-C4 alcohol is ethanol. 32. A formulation according to claim 17 in which the C1-C4 alcohol is a polyol of a C1-C4 alcohol or a polymer of a C1-C4 alcohol. 33. A formulation according to claim 32 in which the polyol of a C1-C4 alcohol is a glycol, propylene glycol, polyethylene glycol, or combinations thereof. 34. A formulation according to claim 17 in which the C1-C4 alcohol is present in an amount of 10 to 30w/w %. 35. A formulation according to claim 17 in which the di- and/or mono-(electron transfer agent) phosphate compound is selected from the group consisting of hydroxy chroman phosphate compounds, phosphate compounds of quinols being the reduced forms of vitamin K1 and ubiquinone, hydroxy carotenoid phosphate compounds, calciferol phosphate compounds, and ascorbic acid phosphate compounds. 36. A formulation according to claim 35 in which the hydroxy chroman phosphate compounds are selected from the group consisting of alpha, beta, gamma, and delta tocol phosphate compounds, in enantiomeric and racemic forms. 37. A formulation according to claim 36 in which the tocol phosphate compound is a tocopheryl phosphate compound or a tocotrienol phosphate compound. 38. A formulation according to claim 37 in which the tocol phosphate compound is selected from the group consisting of di-tocopheryl phosphate compounds, di-tocopheryl di-phosphate compounds, di-tocotrienol phosphate compounds, mono-tocopheryl phosphate compounds, mono-tocopheryl di-phosphate compounds, and mono-tocotrienyl phosphate compounds. 39. A formulation according to claim 38 in which the tocol phosphate compound is a di-tocopheryl phosphate compound. 40. A formulation according to claim 17 in which the combination is a combination of a di-tocopheryl phosphate compound and a mono-tocopheryl phosphate compound. 41. A formulation according to claim 10 in which the w:w % ratio of mono-tocopheryl phosphate compound to di-tocopheryl phosphate compound is from 4:1 to 1:4. 42. A formulation according to claim 17 in which water is in an amount of 60 to 95w/w %. 43. A formulation according to claim 17 in which the carrier is in the form of vesicles. 44. A formulation according to claim 43 in which the vesicles have a diameter of 50 to 10,000 nm. 45. A formulation according to claim 43 in which the vesicles partially or fully encapsulate the biologically active compound. 46. A carrier according to claim 10 in which the w:w % ratio of mono-tocopheryl phosphate compound to di-tocopheryl phosphate compound is 2:1. 47. A carrier according to claim 1 in which the combination of one or more di-(electron transfer agent) phosphate compounds and one or more mono-(electron transfer agent) phosphate compounds is present in an amount of 1 to 3w/w %. 48. A carrier according to claim 1 in which water is in an amount of 70 to 90w/w %. 49. A carrier according to claim 1 in which the vesicles have a diameter of 100 to 500 nm. 50. A carrier according to claim 1 in which the vesicles have a diameter of 300 to 500 nm. 51. A formulation according to claim 20 in which the biologically active compound is present in an amount of 0.5 to 3w/w %. 52. A formulation according to claim 20 in which the biologically active compound is present in an amount of 0.5 to 2w/w %. 53. A formulation according to claim 40 in which the w:w % ratio of mono-tocopheryl phosphate compound to di-tocopheryl phosphate compound is 2:1. 54. A formulation according to claim 17 in which water is in an amount of 70 to 90w/w %. 55. A formulation according to claim 43 in which the vesicles have a diameter of 100 to 500 nm. 56. A formulation according to claim 43 in which the vesicles have a diameter of 300 to 500 nm.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (83)
Terren Nadia,FRX ; Michelet Jacques,FRX ; Perrin Martine,FRX, Acidic composition based on lipid vesicles and its use in topical application.
Lhner Manfred (Bonn DEX) Posselt Klaus (Bonn DEX) Vogtle-Junkert Ute (Alfter DEX) Wagener Hans H. (Meckenheim DEX), Agents for the treatment of severe pain and preparation of said agents.
Challis Brian Christopher,GB3 ; Guthrie Walter Graham,GB3 ; Roper David Vincent,GB3 ; Trew David Frank,GB3, Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics.
Kenneth B Kirby ; Berno I. R. Pettersson, Jr., Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Lubkin Virginia (One Blackstone Pl. New York NY 10471), Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and appli.
Belly Robert T. (Ithaca NY) Scensny Patricia M. (Rochester NY) Wu Annie L. (Penfield NY) Chen Chung-yuan (Rochester NY), Hydrolyzable compounds which release electron transfer agents and analytical use of same.
Sanjay Kumar IN; Rashmita Sahoo IN; Paramvir Singh Ahuja IN, Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions.
Palepu, Nagesh; Kessler, Dean; Tustian, Alexander K.; Quay, Steven C.; Constantinides, Panayiotis P.; Lambert, Karel J., Method for treating colorectal carcinoma using a taxane/tocopherol formulation.
Ito Shinobu,JPX ; Ogata Eiji,JPX, Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals.
Lucas Juliet Marie ; Trinh Toan ; Dodd Michael Thomas ; Bartolo Robert Gregory, Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins.
Uphues Guenter (Monheim DEX) Ploog Uwe (Haan DEX) Bischof Klaudia (Werne DEX), Process for the production and isolation of monoalkyl phosphoric acid esters.
Baldwin William S. (Minneapolis MN) Willging Stephen M. (Minneapolis MN) Siegel Brock M. (Minneapolis MN), Production of d-alpha-tocopherol from natural plant sources.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Elmhurst NY) Gaylord Norman G. (New Providence NJ), Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Bernard Dominique (Paris FRX) Nguyen Quang Lan (Antony FRX), Stabilized cosmetic or dermatological composition containing several precursors of the same active agent in order to max.
Bob G. Sanders ; Kimberly Kline ; Laurence Hurley ; Robb Gardner ; Marla Menchaca ; Weiping Yu ; Puthucode N. Ramanan ; Shenquan Liu ; Karen Israel, Tocopherols, tocotrienols, other chroman and side chain derivatives and uses therof.
Kurihara-Bergstrom Tamie (New City NY) Liu Puchun (Storrs CT), Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol.
Weissman Donald L. ; Rosenbaum Jerry, Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins.
Meybeck Alain (Courbevoie FRX) Bonte Frederic (Courbevoie FRX) Marechal Christian (Paris FRX), Use of a
상세보기
Meybeck Alain (Courbevoie FRX) Dumas Marc (Colombes FRX) Bonte Frederic (Courbevoie FRX) Marechal Christian (Paris FRX), Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions a.
Meybeck Alain (Courbevoie FRX) Dumas Marc (Colombes FRX) Bonte Frederic (Courbevoie FRX) Marechal Christian (Paris FRX), Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions.
Stella Valentino ; Krise Jeffrey P. ; Zygmunt Jan J. ; Georg Ingrid Gunda, Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof.
Hong Jong Eon,KRX ; Lee Ki Hwa,KRX ; Cho Jun Chul,KRX ; Lee Jang Sob,KRX ; Lee Jung No,KRX ; Chun Ji Min,KRX ; Jang Dong Il,KRX ; Lee Ok Sob,KRX ; Lee Sang Rhin,KRX, Water-in-stable L-ascorbic acid derivative and a method for preparation thereof, and a skin-whitening cosmetic compositi.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.